Both clinical trials will involve an "at home" three-month treatment period
conducted at approximately 35 clinical trial sites throughout the United
States. The nasal formulation of PT-141 currently under development is
presented in a convenient and non-invasive application. Clinical data indicates that PT-141
has a rapid onset of action and may be effective in treating a broad range of
patients suffering from ED. To-date ,
the Company has formed partnerships with Mallinckrodt, a subsidiary of Tyco
Healthcare, and King Pharmaceuticals.

discomfort revive

Carl Spana, CEO and President of
Palatin Technologies. Some important factors which
may cause results to differ materially from such forward-looking statements
include dependence on the companies' abilities to carry out their respective
business plans; dependence on the successful development and commercial
acceptance of PT-141; dependence on the companies' abilities to fund
development of PT-141; dependence on whether a commercial product results from
PT-141 development activities; dependence on the companies' abilities to
establish and successfully complete clinical trials necessary for approval of
PT-141 as a treatment for sexual dysfunction; dependence on the actual results
of the Phase IIb clinical program and the actual amount of time it takes to
complete the program; dependence on the companies' abilities to successfully
collaborate in the development and commercialization of PT-141; dependence on
the availability and cost of raw materials; dependence on the unpredictability
of the duration and results of the U. and BRISTOL, Tenn.,
Palatin Technologies, Inc.

destroying viagra

After
receiving PT-141, some patients have experienced prolonged erections lasting
over 4 hours. In addition, certain prescription drugs and psychogenic issues
may contribute to ED.

viagra impotence

Although the current ED market is primarily served by PDE-5 inhibitors
which target the vascular system, a substantial unmet medical need for
alternative sexual dysfunction therapies exists. Palatin's
strategy is to develop products and then form marketing collaborations with
industry leaders in order to maximize their commercial potential.com. Securities
and Exchange Commission.

About Palatin Technologies, Inc.
Palatin Technologies, Inc.

erections discomfort

endure erectile

The condition is correlated with
increasing age, cardiovascular disease, hypertension, diabetes, hyperlipidemia
and smoking. is a biopharmaceutical company developing
melanocortin-based therapeutics.

medically dysfunction

Some side effects that
research participants have experienced include facial flushing, nausea, bad
taste, post-nasal drip and runny nose, headache, and vomiting . To date,
the Company has formed partnerships with Mallinckrodt, a subsidiary of Tyco
Healthcare , and King Pharmaceuticals. Food and Drug Administration's ("FDA")
review of Investigational New Drug Applications ("IND"), New Drug Applications
("NDA"), and supplemental New Drug Applications, ("sNDA ") and/or the review of
other regulatory agencies worldwide; dependence on compliance with FDA and
other government regulations that relate to King's and Palatin's respective
businesses; dependence on King's and Palatin's abilities to successfully
manufacture PT-141; and dependence on changes in general economic and business
conditions; changes in current pricing levels; changes in federal and state
laws and regulations; changes in competition; unexpected changes in
technologies and technological advances; and manufacturing capacity
constraints. CRANBURY, N. (Amex: PTNKG)
announced today publication of the manuscript entitled "Co-administration Of
Low Doses Of Intranasal PT-141, A Melanocortin Receptor Agonist, and
Sildenafil to Men with Erectile Dysfunction Results in an Enhanced Erectile
Response" in the April 2005 issue of the Urology journal. We anticipate that the nasal formulation of PT-
141 currently under development will be as convenient as oral treatments and
more patient -friendly than invasive treatments for ED, such as injections and
trans-urethral pellets.

veromax discomfort

S. The mechanism of action of PT-141 may offer
important benefits over currently available products for the treatment of ED
because it appears to act on the pathway that controls sexual function without
acting directly on the vascular system. The
companies do not undertake to publicly update or revise any of their forward-
looking statements even if experience or future changes show that the
indicated results or events will not be realized.

destroying discomfort

The Company has one product on the market
generating revenue and a pipeline of product opportunities in development.
The Company's internal research and development capabilities, anchored by its
proprietary MIDAS(TM) technology, are fueling product development . This
new chemical entity is being evaluated in Phase 2 clinical trials to assess
the efficacy and safety profiles of varying doses of this novel compound in
men experiencing erectile dysfunction ("ED") and women experiencing female
sexual dysfunction ("FSD"). The condition is correlated with
increasing age, cardiovascular disease, hypertension, diabetes, hyperlipidemia
and smoking.
The Company's internal research and development capabilities, anchored by its
proprietary MIDAS(TM) technology , are fueling product development.com. King, an S+P 500 Index company, seeks to
capitalize on opportunities in the pharmaceutical industry through the
development, including through in-licensing arrangements and acquisitions, of
novel branded prescription pharmaceutical products in attractive markets and
the strategic acquisition of branded products that can benefit from focused
promotion and marketing and product life-cycle management.

clinically endure

The main objectives of these studies are to
further evaluate safety, treatment duration, patient populations and a range
of doses that will be incorporated into Phase III pivotal trials.
"The initiation of these two double-blind, placebo-controlled Phase IIb
clinical trials is a major milestone in the development of PT-141.
Although the current ED market is primarily served by PDE-5 inhibitors
which target the vascular system, a substantial unmet medical need exists for
alternative sexual dysfunction therapies that are effective, well-tolerated
and easy to use. Based on early clinical data, we
believe that PT-141 should not be contraindicated in patients taking nitrates.

erect veromax

For additional information regarding
Palatin, please visit Palatin Technologies' website at http://www. These forward-looking statements reflect
managements' current views of future events and operations, including, but not
limited to, statements pertaining to the potential development and
commercialization of PT-141, and anticipated results and scheduled completion
of the Phase IIb clinical program for PT-141.
Dr. Some important factors which may cause results
to differ materially from such forward-looking statements include dependence
on the companies ' abilities to carry out their respective business plans;
dependence on the successful development and commercial acceptance of PT-141;
dependence on the companies' abilities to fund development of PT-141;
dependence on whether a commercial product results from PT-141 development
activities; dependence on the companies' abilities to establish and
successfully complete clinical trials necessary for approval of PT-141 as a
treatment for sexual dysfunction; dependence on the companies' abilities to
successfully collaborate in the development and commercialization of PT-141;
dependence on the availability and cost of raw materials; dependence on the
unpredictability of the duration and results of the U.S.

clinically intim

Michael King Jolly, Executive Vice President, Research and Development
of King , stated, "Together with our colleagues at Palatin, we are excited to
begin this important next step in the clinical development program for PT-141. In addition, certain prescription drugs and psychogenic issues
may contribute to ED.

About King Pharmaceuticals
King, headquartered in Bristol, Tennessee, is a vertically integrated
branded pharmaceutical company.

EXECUTIVE OFFICES

KING PHARMACEUTICALS, INC. For example, PDE-5 inhibitors may not be effective in up to
30% of patients and are contraindicated in patients taking nitrates, primarily
for the treatment of cardiovascular disease.

Forward -looking Statements
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and as that term is defined in the Private Securities
Litigation Reform Act of 1995.

viagra intim

King Pharmaceuticals and Palatin Technologies Initiate Phase IIb Clinical Trials Evaluating PT-141 in Patients Suffering from Erectile Dysfunction

About PT-141
PT-141 is the first compound in a new drug class called melanocortin
receptor agonists under development to treat sexual dysfunction.
4 CEDAR BROOK DRIVE, CRANBURY, NEW JERSEY 08512

The Company has one product on the market
generating revenue and a pipeline of product opportunities in development.

clinically organism

The continued successful development of PT-141 is one of the highest
priorities of our research and development team and is progressing as
planned.

Forward-looking Statements
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and as that term is defined in the Private Securities
Litigation Reform Act of 1995.

Palatin Technologies and King Pharmaceuticals Announce Publication of Clinical Study Results of Co-Administration of PT-141 and Viagra(R)

J. Carl Spana, President and Chief Executive Officer of Palatin, stated,
"The results of this preliminary evaluation are consistent with the concept
that co-administration of these two therapies, each with a different yet
complementary mechanism of action, may constitute a treatment alternative for
ED patients for whom higher doses of a single therapy are not effective or are
not well-tolerated.

About King Pharmaceuticals
King, headquartered in Bristol, Tennessee, is a vertically integrated
branded pharmaceutical company.

veromax erect

BRISTOL, Tenn."
The non-diabetic Phase IIb clinical trial is scheduled to conclude in
mid-2006, while the conclusion of the diabetic Phase IIb clinical is scheduled
to follow in the second half of 2006. It is estimated that some degree of ED affects one half
of all men over the age of 40 and that 150 million men worldwide suffer from
ED. The mechanism of action of PT-141 may offer important
benefits over currently available products for the treatment of ED because it
acts on the pathway that controls sexual function without acting directly on
the vascular system . Clinical data indicates that PT-141 may be effective in
treating a broad range of patients suffering from ED.

inconvenience impotence

Additionally, the clinical trials will evaluate a range of PT-141
intranasal doses between 5 mg and 15 mg.

About ED
ED is defined as the consistent inability to attain and maintain an
erection sufficient for sexual intercourse.

About Erectile Dysfunction (ED)
ED is defined as the consistent inability to attain and maintain an
erection sufficient for sexual intercourse. These forward-looking statements reflect
managements' current views of future events and operations, including, but not
limited to, statements pertaining to the potential development and
commercialization of PT-141. Food and Drug
Administration's ("FDA") review of Investigational New Drug Applications
("IND"), New Drug Applications ("NDA"), and supplemental New Drug
Applications , ("sNDA") and/or the review of other regulatory agencies
worldwide; dependence on compliance with FDA and other government regulations
that relate to King's and Palatin's respective businesses; dependence on
King's and Palatin's abilities to successfully manufacture PT-141; and
dependence on changes in general economic and business conditions; changes in
current pricing levels; changes in federal and state laws and regulations;
changes in competition; unexpected changes in technologies and technological
advances; and manufacturing capacity constraints.

inconvenience destroying

The
second clinical trial will similarly evaluate 265 diabetic patients with ED. We believe
the data from this extensive Phase IIb program will allow us to confidently
select doses, end points and treatment periods for use in the design of the
pivotal Phase III trials," commented Dr. For example,
unlike PDE-5 inhibitors which are contraindicated in patients taking nitrates,
primarily for the treatment of cardiovascular disease, current animal data
indicates that PT-141 may not be contraindicated in patients taking nitrates. King, an S+P 500 Index company, seeks to
capitalize on opportunities in the pharmaceutical industry through the
development, including through in-licensing arrangements and acquisitions, of
novel branded prescription pharmaceutical products in attractive markets and
the strategic acquisition of branded products that can benefit from focused
promotion and marketing and product life-cycle management. The companies do not undertake to publicly update or
revise any of their forward-looking statements even if experience or future
changes show that the indicated results or events will not be realized. Co-
administration therapy resulted in a significantly enhanced duration and
quality of erectile activity, compared to Viagra monotherapy, as measured by
both RigiScan(R) and by patient self-assessment scores, respectively . In this
group of nineteen patients, co-administration did not result in new side
effects or in an increase in frequency or severity of side effects compared to
monotherapy.

impotence premature

, King
Pharmaceuticals (NYSE: KGPTN)
announced today that they have initiated patient enrollment in two double-
blind , placebo-controlled Phase IIb clinical trials of PT-141 in patients with
erectile dysfunction (ED ). Many patients are
contraindicated for, or non-responsive to, PDE-5 inhibitors.S.

erections premature

is a biopharmaceutical company developing
melanocortin-based therapeutics.S.

erectile fraction

PT-141 is a
melanocortin agonist that King and Palatin are jointly developing for the
treatment of male and female sexual dysfunction.

viagra clinically

The first Phase IIb clinical trial will evaluate the safety and efficacy
of PT-141 in 560 non-diabetic patients suffering from mild to severe ED. Other important factors that may cause actual results to differ
materially from the forward-looking statements are discussed in the "Risk
Factors" section and other sections of King's Form 10-K for the year ended
December 31, 2004 and Form 10-Q for the first quarter ended March 31, 2005,
and Palatin's Form 10-K for the year ended June 30, 2004 and Form 10-Q for the
third quarter ended March 31, 2005, which are on file with the U. Preliminary results
of this clinical trial were previously released by Palatin Technologies on
June 8, 2004 . Palatin's
strategy is to develop products and then form marketing collaborations with
industry leaders in order to maximize their commercial potential. Other important factors
that may cause actual results to differ materially from the forward-looking
statements are discussed in the "Risk Factors" section and other sections of
King's Form 10-K for the year ended December 31, 2004 and Form 10-Q for the
second quarter ended September 30, 2004, and Palatin's Form 10-K for the year
ended June 30, 2004 and Form 10-Q for the second quarter ended December 31,
2004, which are on file with the U.

vaage erectile

and CRANBURY, N.
Dr.
501 FIFTH STREET, BRISTOL, TENNESSEE 37620

PALATIN TECHNOLOGIES, INC."

About PT-141
PT-141 is the first compound in a new drug class called melanocortin
receptor agonists and is under development to treat sexual dysfunction. About 150 million men worldwide and 30 million American men
suffer from ED.palatin.

ejaculation vaage

palatin.
The purpose of this initial nineteen-patient, co-administration study was
to evaluate the potential additive effect of co-administration of Viagra(R)
(sildenafil) and PT-141 to men with erectile dysfunction (ED).
Current literature indicates that about 40% of all patients who receive an
initial prescription for a PDE-5 inhibitor do not renew the prescription due
chiefly to adverse side effects, drug interaction issues, and/or the lack of
an acceptable level of response. It is estimated that 50% of all men over the age of 40
suffer from ED. For additional information regarding
Palatin, please visit Palatin Technologies' website at http://www.

revive erections

This new
chemical entity is being evaluated in Phase IIb clinical trials studying the
efficacy and safety profile of varying doses of this novel compound in men
experiencing erectile dysfunction ("ED") and women experiencing female sexual
dysfunction ("FSD"). Securities and Exchange Commission.

medically clinically

Current literature indicates that about one half of all patients who receive
an initial prescription for a PDE-5 inhibitor do not renew the prescription
due chiefly to adverse side effects, drug interaction issues, and/or the lack
of an acceptable level of responsiveness.

About Palatin
Palatin Technologies, Inc.